摘要
目的探究纤溶酶注射剂联合羟乙基淀粉治疗进展性脑梗死的临床疗效。方法以我院2013年1月至2015年8月收治的120例进展性脑梗死患者为研究对象,按入院先后顺序分为观察组60例和对照组60例。对照组给予奥扎格雷钠联合拜阿司匹林常规治疗,观察组给予纤溶酶注射剂联合羟乙基淀粉治疗,两组疗程均为14 d。比较两组治疗前后的CCS评分以及临床疗效。结果治疗后,两组患者CCS评分均显著降低,且观察组降低程度更加明显,差异具有统计学意义(P<0.05)。观察组患者总有效率(95.0%)明显高于对照组(83.3%),差异具有统计学意义(P<0.05)。结论纤溶酶注射剂联合羟乙基淀粉治疗进展性脑梗死,能更有效改善患者病情,对患者预后有更加积极的影响,可在临床治疗过程中合理采用。
Objective To explore the clinical efficacy of plasmin injection combined with hydroxyethyl starch in the treatment of progressive cerebral infarction（PCI）. Methods 120 cases of PCI patients admitted to our hospital from January 2013 to August 2015 were selected and divided into observation group（60 cases） and control group（60 cases） according to the admission sequence. The control group was given sodium ozagrel combined with bayaspirin conventional therapy, the observation group was given plasmin injection combined with hydroxyethyl starch treatment. The CCS scores before and after treatment, clinical efficacy in two groups were compared. Results A fter treatment, the CCS scores in two groups decreased significantly, and the droop degree in observation group was more obvious, with statistical difference（P〈0.05）. The total effective rate in observation group was 95.0%, significantly higher than 83.3% in control group, the difference was statistical（P〈0.05）. Conclusions Plasmin injection combined with hydroxyethyl starch in treatment of progressive cerebral infarction can effectively improve patient＇s conditions, and has more positive influence on patients＇ prognosis, which can be reasonable used in clinic.
出处
《临床医学工程》
2016年第7期913-914,共2页
Clinical Medicine & Engineering
关键词
脑梗死
纤溶酶
羟乙基淀粉
颈内动脉粥样硬化
临床疗效
Cerebral infarction
Plasmin
Hydroxyethyl starch
Carotid atherosclerosis
Clinical efficacy
